The Triple B Study: Bumps, Babies and Beyond is an innovative Australian study of approximately 1600 families. The project is a longitudinal pregnancy cohort which examines a wide range of biopsychosocial factors that relate to the health and development of Australian children and families.
Prevention and early intervention
Governments, policy experts, researchers and randomly selected members of communities all support the idea of greater co-ordination of efforts aimed at reducing alcohol-related harm.
The Triple B study (Bumps, Babies and Beyond) is a large NHMRC-funded birth cohort study which examines the effects of substance use in pregnant women and their partners during the prenatal period on infant development and family functioning.
Mental health and substance use disorders account for more years of life lost due to disability than any other disorders. These disorders often occur together (comorbidity), affecting more than 300,000 Australians every year.
The increased use of psychostimulants in Australia is a major concern. People using psychostimulants often do not access traditional treatment services, as their need is often greatest outside of regular office hours.
Alcohol use during pregnancy has been associated with a number of adverse pregnancy outcomes including miscarriage, premature birth, still birth and low birth weight.
To review, update and add new information reflecting current drug trends to inform content included on the National Drugs Campaign (NDC) website.
Cannabis use is a significant problem among Australian adolescents. There is evidence suggesting that substance use interventions for adolescents must target immediate affective responses to thoughts of using the substance.
This project is a pilot study to establish the feasibility and methods for a new Australian birth cohort of 1800-2000 Australian families (The Triple B Study: Bumps, Babies and Beyond).
Despite the increasing use of the internet by the general community to access information about alcohol/other drug use and related conditions, there remains no central portal through which people can reliably access a range of evidence-based information and treatment for alcohol/other drug use.